Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Pimecrolimus, tacrolimus keep in check pediatric AD
New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
